CIK 0001178711
PRTK Paratek Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Dec 22, 2022.
In brief
Paratek Pharmaceuticals, Inc. (PRTK) has 16 SEC Form 4 filings on file from 4 insiders, the latest filed on Dec 22, 2022. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
12 open-market trades have been scored at PRTK. The newest: Michael Bigham (Exec. Chairman of the Board) sold $31k of stock on Dec 21, 2022, filed Dec 22, 2022, scored 20 (weak), under a 10b5-1 plan. The largest of the 12 shown: Evan Loh (CEO) sold $196k on Dec 12, 2022, scored 32 (weak), under a 10b5-1 plan. 4 insiders sold within 14 days of each other around Dec 21, 2022.
Last 90 days
Signals
Open-market buys and sells at Paratek Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Michael Bigham Exec. Chairman of the Board sell | $31k 15,750 shares | -1% | - | |
| 10Weak | Randall B. Brenner Chief Development & Regulatory sell | $9,033 4,539 shares | -1% | - | |
| 10Weak | William M. Haskel CLO, General Counsel & Sec. sell | $14k 7,007 shares | -2% | - | |
| 26Weak | Evan Loh CEO sell | $47k 23,489 shares | -2% | - | |
| 25Weak | Michael Bigham Exec. Chairman of the Board sell | $101k 51,375 shares | -4% | - | |
| 17Weak | Randall B. Brenner Chief Development & Regulatory sell | $58k 29,282 shares | -8% | - | |
| 18Weak | William M. Haskel CLO, General Counsel & Sec. sell | $75k 37,994 shares | -9% | - | |
| 32Weak | Evan Loh CEO sell | $196k 99,750 shares | -8% | - | |
| 15Weak | Michael Bigham Exec. Chairman of the Board sell | $21k 6,000 shares | -0% | - | |
| 10Weak | Randall B. Brenner Chief Development & Regulatory sell | $12k 3,516 shares | -1% | - | |
| 10Weak | William M. Haskel CLO, General Counsel & Sec. sell | $15k 4,382 shares | -1% | - | |
| 25Weak | Evan Loh CEO sell | $31k 8,805 shares | -1% | - |
Transactions
Every row filed, 24 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 20, 2022 | Michael Bigham Exec. Chairman of the Board | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 1,225,452 | Dec 22, 2022 |
| Dec 20, 2022 | Randall B. Brenner Chief Development & Regulatory | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 339,851 | Dec 22, 2022 |
| Dec 20, 2022 | William M. Haskel CLO, General Counsel & Sec. | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 414,807 | Dec 22, 2022 |
| Dec 20, 2022 | Evan Loh CEO | AGrant or award Common Stock | +52,500 | $0.00 | $0 | 1,231,687 | Dec 22, 2022 |
| Dec 21, 2022 | Randall B. Brenner Chief Development & Regulatory | SOpen-market sale Common Stock10b5-1 | -4,539 | $1.99 | $9,033 | 335,312 | Dec 22, 2022 |
| Dec 21, 2022 | William M. Haskel CLO, General Counsel & Sec. | SOpen-market sale Common Stock10b5-1 | -7,007 | $1.99 | $14k | 407,800 | Dec 22, 2022 |
| Dec 21, 2022 | Evan Loh CEO | SOpen-market sale Common Stock10b5-1 | -23,489 | $1.99 | $47k | 1,208,198 | Dec 22, 2022 |
| Dec 21, 2022 | Michael Bigham Exec. Chairman of the Board | SOpen-market sale Common Stock10b5-1 | -15,750 | $1.99 | $31k | 1,209,702 | Dec 22, 2022 |
| Dec 12, 2022 | Michael Bigham Exec. Chairman of the Board | SOpen-market sale Common Stock10b5-1 | -19,484 | $1.98 | $39k | 1,212,343 | Dec 14, 2022 |
| Dec 12, 2022 | Evan Loh CEO | SOpen-market sale Common Stock10b5-1 | -37,831 | $1.98 | $75k | 1,241,106 | Dec 14, 2022 |
| Dec 12, 2022 | William M. Haskel CLO, General Counsel & Sec. | SOpen-market sale Common Stock10b5-1 | -14,410 | $1.98 | $29k | 423,391 | Dec 14, 2022 |
| Dec 12, 2022 | Randall B. Brenner Chief Development & Regulatory | SOpen-market sale Common Stock10b5-1 | -11,105 | $1.98 | $22k | 343,028 | Dec 14, 2022 |
| Dec 13, 2022 | Evan Loh CEO | SOpen-market sale Common Stock10b5-1 | -61,919 | $1.96 | $121k | 1,179,187 | Dec 14, 2022 |
| Dec 13, 2022 | William M. Haskel CLO, General Counsel & Sec. | SOpen-market sale Common Stock10b5-1 | -23,584 | $1.96 | $46k | 399,807 | Dec 14, 2022 |
| Dec 13, 2022 | Randall B. Brenner Chief Development & Regulatory | SOpen-market sale Common Stock10b5-1 | -18,177 | $1.96 | $36k | 324,851 | Dec 14, 2022 |
| Dec 13, 2022 | Michael Bigham Exec. Chairman of the Board | SOpen-market sale Common Stock10b5-1 | -31,891 | $1.96 | $63k | 1,180,452 | Dec 14, 2022 |
| Oct 28, 2022 | Michael Bigham Exec. Chairman of the Board | SOpen-market sale Common Stock10b5-1 | -6,000 | $3.47 | $21k | 1,231,827 | Nov 1, 2022 |
| Oct 28, 2022 | Randall B. Brenner Chief Development & Regulatory | SOpen-market sale Common Stock10b5-1 | -3,516 | $3.47 | $12k | 354,133 | Nov 1, 2022 |
| Oct 28, 2022 | William M. Haskel CLO, General Counsel & Sec. | SOpen-market sale Common Stock10b5-1 | -4,382 | $3.47 | $15k | 437,801 | Nov 1, 2022 |
| Oct 28, 2022 | Evan Loh CEO | SOpen-market sale Common Stock10b5-1 | -8,805 | $3.47 | $31k | 1,278,937 | Nov 1, 2022 |
| Oct 25, 2022 | Michael Bigham Exec. Chairman of the Board | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 1,237,827 | Oct 27, 2022 |
| Oct 25, 2022 | Randall B. Brenner Chief Development & Regulatory | AGrant or award Common Stock | +8,500 | $0.00 | $0 | 357,649 | Oct 27, 2022 |
| Oct 25, 2022 | William M. Haskel CLO, General Counsel & Sec. | AGrant or award Common Stock | +9,250 | $0.00 | $0 | 442,183 | Oct 27, 2022 |
| Oct 25, 2022 | Evan Loh CEO | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 1,287,742 | Oct 27, 2022 |
Insiders
Everyone who has filed a Form 4 here.
- Michael BighamExec. Chairman of the Board
- Randall B. BrennerChief Development & Regulatory
- William M. HaskelCLO, General Counsel & Sec.
- Evan LohCEO
Questions about PRTK
Answered from the filings on this page, as of the latest one.
Are insiders buying PRTK?
No. In the last 90 days no insider at Paratek Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade PRTK on the open market?
Michael Bigham (Exec. Chairman of the Board) sold $31k of PRTK on Dec 21, 2022 and filed the Form 4 on Dec 22, 2022. InsiderTell scored 20 (weak), under a 10b5-1 plan, with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Paratek Pharmaceuticals, Inc.?
4 people have filed a Form 4 at Paratek Pharmaceuticals, Inc., among them Michael Bigham (Exec. Chairman of the Board), Randall B. Brenner (Chief Development & Regulatory), William M. Haskel (CLO, General Counsel & Sec.). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.